← Back
Data updated: Jun 28, 2026
QOL MEDCL
Specialty Pharmaceuticals
QOL MEDCL is a specialty pharmaceutical company with 3 FDA-approved products.
1988
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules 1 Biologics
QOL MEDCL's Key Drugs
QOL MEDCL's core commercial portfolio centers on GIMOTI — its most strategically important drugs approved in the last 15 years.
QOL MEDCL's Recent FDA Approvals
New NDA/BLA approvals for QOL MEDCL over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
QOL MEDCL's Therapeutic Areas
Disease areas where QOL MEDCL has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
QOL MEDCL Pipeline Snapshot
Active clinical trials for QOL MEDCL across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GIMOTI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1988-12-22
- Latest
- 2026-02-09
- Applications
- 3